New oral drug aims to tame ulcerative colitis Flare-Ups

NCT ID NCT07686081

Not yet recruiting Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether the oral drug ponesimod can help people with moderately to severely active ulcerative colitis achieve remission. Participants receive either ponesimod or a placebo daily for 16 weeks, with an option to continue on ponesimod for another 36 weeks. The study measures how many people reach clinical remission and symptom improvement by week 16.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ponesimod (also known as VSP-128)
What this could lead to: If successful, ponesimod could offer a new oral treatment option for people with moderate-to-severe ulcerative colitis who have not responded to other therapies.
What could go wrong: This is a Phase 3 trial, but results may not confirm benefit. Ponesimod can have side effects, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Vanda Investigational Site

Chula Vista, California, 91910, United States
Vanda Investigational Site

Nashville, Tennessee, 37211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.